Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.45 |
| ▸ | HTR2A | P28223 | 14/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PKLR | P30613 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL5999499 | 0.92 | SLC6A4 (0.45) | SLC6A4HTR2AKCNH2 | |
| Formic Acid SCHEMBL6000270 | 0.88 | FFAR1 (0.39) | SLC6A4HTR2AKCNH2FFAR1RAB9A | |
| SCHEMBL6000267 | 0.82 | FFAR1 (0.38) | SLC6A4HTR2AKCNH2FFAR1RAB9A | |
| Formic Acid SCHEMBL6000448 | 0.80 | HTR2A (0.37) | SLC6A4HTR2AKCNH2RAB9A | |
| Formic Acid SCHEMBL5999505 | 0.80 | CHRM2 (0.36) | SLC6A4HTR2AKCNH2FFAR1 | |
| SCHEMBL5999798 | 0.78 | SLC6A4 (0.52) | SLC6A4HTR2AKCNH2 | |
| Formic Acid SCHEMBL5999788 | 0.77 | HTR2A (0.46) | SLC6A4HTR2AKCNH2 | |
| SCHEMBL5999503 | 0.74 | KCNH2 (0.34) | SLC6A4HTR2AKCNH2FFAR1 | |
| SCHEMBL6000317 | 0.72 | HTR2A (0.41) | SLC6A4HTR2AKCNH2 | |
| SCHEMBL6000347 | 0.72 | SLC6A4 (0.51) | SLC6A4HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | SLC6A4 150/4885HTR2A 7/4885KCNH2 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.